

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	INVION LIMITED
ABN	76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DR GREG COLLIER
Date of last notice	19 March 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Change to indirect holdings.
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect holdings are Beacon Super Fund Pty Ltd ATF Beacon Super Fund of which Dr Collier is a director and beneficiary; Barwon Biotechnology Pty Ltd of which Dr Collier is a director and shareholder; and Fusion Biosciences Pty Ltd of which Dr Collier is a director.
Date of change	12 February 2019
Total No. of securities held prior to change	23,437,599 fully paid ordinary shares (indirectly held).
Class	Fully paid ordinary shares Unlisted Share Options

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	8,333,333 Fully paid ordinary shares 136,288,073 Share options exercisable at \$0.03 each on or before 12 February 2023 (IVXAT).
Number disposed	Nil.
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil Consideration. Share Options issued following Shareholder Approval at EGM held 30 January 2019.
Total No. of securities held after change	31,770,932 fully paid ordinary shares (indirectly held). 136,288,073 Share options exercisable at \$0.03 each on or before 12 February 2023 (IVXAT).
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Share Options issued following Shareholder Approval at EGM held 30 January 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
Interest acquired	n/a
Interest disposed	n/a

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	n/a
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.